Olivier S Descamps
Overview
Explore the profile of Olivier S Descamps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
3814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elshorbagy A, Vallejo-Vaz A, Barkas F, Lyons A, Stevens C, Dharmayat K, et al.
Eur Heart J
. 2025 Jan;
PMID: 39801189
Background And Aims: Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and...
2.
Snel M, Descamps O
Acta Cardiol
. 2023 Sep;
79(3):311-318.
PMID: 37767917
In 2019, the European Atherosclerosis Society (EAS) published updated guidelines, recommending even lower blood cholesterol targets than previously. In patients with familial hypercholesterolaemia (FH), who have very elevated blood cholesterol...
3.
Santos R, Ruzza A, Hovingh G, Stefanutti C, Mach F, Descamps O, et al.
Lancet Diabetes Endocrinol
. 2022 Sep;
10(10):732-740.
PMID: 36075246
Background: The HAUSER-RCT study showed that 24 weeks of evolocumab (a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) in paediatric patients with heterozygous familial hypercholesterolaemia was safe and improved lipid...
4.
Belgian data of ODYSSEY APPRISE: stringent LDL-c targets are in reach when using all available tools
Verdickt S, Van der Schueren B, Vangoitsenhoven R, Descamps O, Mertens A
Int J Clin Pract
. 2021 Sep;
75(12):e14916.
PMID: 34551183
Background: As lipid targets became more stringent in the latest ESC/EAS guidelines, many patients on statin monotherapy are left above their risk-based target, increasing the need for lipid-lowering therapies. The...
5.
Futema M, Ramaswami U, Tichy L, Bogsrud M, Holven K, Roeters van Lennep J, et al.
Atherosclerosis
. 2021 Jan;
319:108-117.
PMID: 33508743
Background And Aims: Familial hypercholesterolaemia (FH) is commonly caused by mutations in the LDLR, APOB or PCSK9 genes, with untreated mean low density lipoprotein-cholesterol (LDL-C) concentrations being elevated in APOB...
6.
Descamps O, Rietzschel E, Laporte A, Buysschaert I, De Raedt H, Elegeert I, et al.
Acta Cardiol
. 2020 Sep;
76(3):227-235.
PMID: 32964780
Background: Familial hypercholesterolaemia (FH) is underdiagnosed in most countries. We report our first experience from a national pilot project of cascade screening in relatives of FH patients. Methodology: Participating specialists...
7.
Zheng K, Kaiser Y, van Olden C, Santos R, Dasseux J, Genest J, et al.
Atherosclerosis
. 2020 Sep;
311:13-19.
PMID: 32919280
Background And Aims: Infusion of high-density lipoprotein (HDL) mimetics failed to induce regression of atherosclerosis in recent randomized clinical trials. However, patients in these previous trials had normal levels of...
8.
Santos R, Ruzza A, Hovingh G, Wiegman A, Mach F, Kurtz C, et al.
N Engl J Med
. 2020 Sep;
383(14):1317-1327.
PMID: 32865373
Background: Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in...
9.
Nordestgaard B, Langlois M, Langsted A, Chapman M, Aakre K, Baum H, et al.
Atherosclerosis
. 2020 Jan;
294:46-61.
PMID: 31928713
The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory...
10.
Wilemon K, Patel J, Aguilar-Salinas C, Ahmed C, Alkhnifsawi M, Almahmeed W, et al.
JAMA Cardiol
. 2020 Jan;
5(2):217-229.
PMID: 31895433
Importance: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to...